Obalon Therapeutics Inc. Announces Closing of $16.6 Million Public Offering

SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) — Obalon Therapeutics Inc. (Nasdaq: OBLN) (the ?Company?), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced the closing of its previously announced underwritten public offering of (i) 2,015,000 shares of common stock together with common stock purchase warrants (the ?purchase warrants?) to purchase 1,511,250 shares of common stock, (ii) 1,735,000 pre-funded warrants, with each pre-funded warrant exercisable for one share of common stock, together with common warrants to purchase 1,301,250 shares of common stock and (iii) 412,500 shares of common stock and 421,875 purchase warrants pursuant to the over-allotment option. The shares of common stock and accompanying purchase warrants were sold together at a combined public offering price of $4.00 per share, and the pre-funded